2cureX strengthen its patent portfolio with the granting of a new European patent
Press releases regulatory
2cureX AB (“2cureX”) is pleased to announce the grant of European patent No. 3164709 “Identifying compounds modifying a cellular phenotype”. The patent protects the use of patient-derived micro-tumors for cancer treatment design. Together with 2cureX’s existing patent portfolio, the patent provides a broad protection of the company’s IndiTreat technology in its European launch markets. The patent is valid until July 2035. The patent is currently also being prosecuted in territories outside Europe (e.g. USA).
The IndiTreat technology generates thousands of small micro-tumors (tumoroids) from a small tissue sample obtained from the patient’s primary tumor or metastasis. 2cureX’s patents protect the application of the tumoroid technology in a clinical setting where hundreds of different mono- and combination therapies are tested on the individual patient’s tumoroids.
The objective is that IndiTreat shall help oncology caregivers determine to which cancer treatment the patient is sensitive and to which the patient is resistant. IndiTreat is currently being clinically validated in both colorectal cancer and ovarian cancer, and the market launch is planned in Denmark, Germany, Sweden and Great Britain in 2020.
“This is an important recognition of 2cureX’s central role in the design of efficacious treatments for individual cancer patients” says Grith Hagel, Inventor and Head of Development at 2cureX and she continues; “the IndiTreat technology has already shown its capacity in colorectal cancer and ovarian cancer patients showing its potential to become an important tool for individualized treatment design in the very near future.”
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO;
Phone: +45 22 11 53 99;
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 22nd, 2018.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).